

Enrollment Form

Phone: 844-NEX-4321 (844-639-4321) • Fax: 844-232-2618

TO GET STARTED, COMPLETE THE ENROLLMENT FORM AND FAX IT TO 844-232-2618.

PLEASE CHECK ALL BOXES THAT APPLY AND	COMPLETE THE APPROPRIATE SECTION(S) OF THE FORM		
Patient Benefit Investigation Prescription Order			
SPECIALTY PHARMACY ORDE	R FOR ASSIGNMENT OF BENEFITS ONLY:		
Please select one fulfillment option to indicate your preference. Note the Accredo Pharmacy CVS Specialty Pharmacy Humana Specialty Pharmacy	e ASPN Pharmacies, LLC		
PATIENT INFORMATION			
Last Name:	First Name: MI:		
Date of Birth: Primary Language:			
Address:	City: Zip Code:		
Phone: H	ome Cell Email:		
Special Instructions:			
Current Medications:			
INSURANCE INFORMATION			
PLEASE COMPLETE ALL THAT APPLY AND INCLUDE A FRON	T AND BACK COPY OF INSURANCE CARD FOR EACH TYPE OF INSURANCE		
Patient has no insurance and/or does not want insurance billed. Requests	for Self Pay option available at preferred Specialty Pharmacy.		
Prescription Drug Card	Medical Insurance		
Plan Name:	Plan Name:		
Payer Phone: BIN:	Payer Phone:		
PCN: Policy #: Group #:	Policy #: Group #:		
Policy Holder Information (If different from patient)	Policy Holder Information (If different from patient)		
Name:	Name:		
Date of Birth:			
Employer:			
Relationship to Patient:	Relationship to Patient:		

PATIENT AUTHORIZATION (REQUIRED if "Prescription Order" has been requested above)

I understand that in order for Merck Sharp & Dohme B.V., a subsidiary of Merck & Co., Inc., and Lash (the company that will conduct reimbursement support on behalf of Merck) to provide me with assistance, Lash and its administrators (collectively, "Lash") will need to obtain, review, use, and disclose my personal health information related to my treatment with NEXPLANON, information on my request form, and any prescription

PATIENT AUTHORIZATION (continued)

for NEXPLANON® (etonogestrel implant) (my "PHI"). I authorize my physician, pharmacy(ies), and my health plan(s) to disclose my PHI to Lash as necessary to complete the insurance investigation process. I further authorize Lash and the Specialty Pharmacies (Accredo Pharmacy, AllianceRx Walgreens Prime, ASPN Pharmacies, LLC, CVS Specialty Pharmacy, Humana Specialty Pharmacy, or Magellan Rx Pharmacy) and their respective affiliates to exchange my PHI to provide support and to disclose the information to my health plan(s) and their contractors for the purpose of coordination of benefits, reimbursement support, investigating insurance coverage and coordination of the delivery, receipt and storage of my prescription medication for NEXPLANON for the sole purpose of administration to me by my prescribing provider named above.

I authorize the Specialty Pharmacy to use my PHI to contact me via mail, telephone, text, or email in connection with information related to this Enrollment Form. In order for the Specialty Pharmacy to ship my prescription medication for NEXPLANON directly to my prescribing provider, I authorize the Specialty Pharmacy to communicate with my prescribing provider about my PHI in order to coordinate the delivery, receipt, and storage of my prescription medication for NEXPLANON for the sole purpose of administration of my prescribing provider at my next scheduled appointment. I understand that my PHI disclosed pursuant to this Authorization may no longer be protected by certain federal privacy laws and may be re-disclosed by the recipient, but that Lash has agreed to use my PHI only for the purposes described herein.

I understand that if I do not sign this Authorization, that will not affect my receipt of treatment (including with NEXPLANON) or of health insurance benefits, but that I will not be able to obtain certain assistance provided by Lash on behalf of Merck. I understand that I may cancel this Authorization at any time by mailing a written request for such cancellation to Lash, PO Box 741, Monroeville, PA, 15146-0741. I understand that canceling my Authorization will not affect uses and disclosures of PHI already made in reliance on the Authorization before my cancellation is received by Lash.

I understand that Merck may assign or transfer the Customer Support Center for NEXPLANON (CSCN) in whole or in part, directly or indirectly, to an affiliated entity ("Affiliate") or an entity that is not affiliated with Merck in the event of a divestiture, dissolution, spin-off, or other transaction ("NewCo"), and I authorize the Program Administrators to transfer my PHI to such Affiliate or NewCo, including their respective contractors or other representatives. I understand that, in the event of such an assignment or transfer, Merck and/or the applicable Affiliate or NewCo will notify me of the assignment or transfer, including my option to withdraw from the Program. I understand that any future offerings by an Affiliate or NewCo may differ from the CSCN and will be subject to eligibility criteria, terms, and conditions established by an Affiliate or NewCo that could affect my participation in the future.

If I do not cancel this Authorization, the Authorization will expire 15 months from the date of signature (or the maximum period allowed by applicable state law, if less than 15 months). Merck has retained Lash and the Specialty Pharmacies to provide support to customers, including reimbursement support. Information and questions related to the information provided in regard to this request should be referred directly to Lash. Merck personnel are not aware of patient-specific reimbursement information and are not permitted to discuss such information with customers. I have read this document or have had it explained to me. I understand that I may request a copy of this Authorization once it has been signed.

Patient Signature:	Date:
Print Name:	Date:
Relationship to patient if signing on their behalf:	Date:
	reality of the management

If you have questions about completing this form or need additional information, please call 844-NEX-4321 (844-639-4321). Thank you.

Patient Last Name: Patient Fin	rst Name:	Patient Date o	ED if "Prescription Order" has been requested) Patient Date of Birth:	
Dispense: 1 Rx NEXPLANON® (etonogestrel implant) 68 mg	Days supplied: _3	years Refills: <u>0</u> Allergies:		
SIG: To be inserted one time by prescriber subdermally	Date of Last Men	ses:		
Anticipated Insertion Date:				
Product Substitution Permitted (Signature)	Date	Dispense as Written (Signature)	Date	
I certify that I have completed train	ing for NEXPLANO	N. If not certified, please contact your sales rep	resentative.	
DDFGGDDFD INFORMATION /			· · · · · · · · · · · · · · · · · · ·	
PRESCRIBER INFORMATION (prescrib		· ,	ined on NEXPLANUN)	
Last Name: Cho		First Name: Jennifer		
Practice/Facility Name: Bergen County Gynecolog				
Practice/Facility Address: 106 Grand Ave Suite 300		_{City:} Englewoo	d	
Office Contact: Crystal Leslie	Phon	e: 201-608-0670 Fax: _	201-781-7821	
Office Contact: Crystal Leslie State: NJ Zip Code: 07631 Tax ID #: 8111	369894	State Medical License #:		
Please indicate the diagnosis code(s): Z30.017	Z30.46	Other:		
For ARNP, NP & PA, and other, collaborative physician agreement is with:		NPI#:	Date:	
DDECORIDED AUTHORIZATION				
PRESCRIBER AUTHORIZATION				
MUST CONTAIN ORIGINAL SIGNATURE This request has been prepared exclusively by the physician or physician offi request ("my Practice").	ce identified in this	I understand that information concerning prograstatistical or other purposes and provided to Me		
 My Practice has obtained written authorization from the patient identified in disclose the patient's personal health information (PHI), including information patient's medical condition and prescription medications and the information Enrollment Form, as well as the information included in this request, to the C 	n relating to the n disclosed in this customer Support	 I understand that the Program reserves the righ records to verify the information provided herein auditor enters into an appropriate agreement w medical privacy). 	n, excluding patient-identifiable data (unless th	
Center for NEXPLANON ("CSCN"), sponsored by Merck Sharp & Dohme Corp subsidiary of Merck & Co., Inc., the administrators of the Program, including		 I consent to receive communications related to I understand that Merck may assign the CSCN a 		

- other affiliates, and for the CSCN to use and disclose the information for the purposes of benefits investigation and reimbursement support.
- My Practice has provided the patient identified in this request with the notices necessary to comply with all federal and state laws and regulations relating to medical and/or health privacy. including, but not limited to, the HIPAA Privacy Rule, codified at 45 C.F.R. Parts 160 and 164, as amended from time to time.
- If my patient is a minor, I certify that either 1) this patient's parent or quardian has consented to the patient's treatment with NEXPLANON (as allowable under the law of the state in which I practice), or 2) I, or a physician in my Practice, have determined that this patient has the capacity to consent to treatment with NEXPLANON under the law of the state in which I practice (and that consent of a parent or guardian is not required).
- . I certify that I am authorized, pursuant to the laws of my state of licensure, to prescribe NEXPLANON
- NOTICE: In the event that my patient's insurer provides coverage via an assignment of benefits, I understand that this Enrollment Form may also serve as a prescription that can, at my request, be forwarded to the relevant specialty pharmacy. However, I understand that prescribing and dispensing laws and regulations vary by state and that this form may NOT be consistent with the requirements (e.g., content or format) for a valid prescription in my state, in which case I am responsible for submitting a prescription to the relevant specialty pharmacy (or for including such form with this Enrollment Form) in a manner and on a form consistent with the requirements in my state. By submitting this Enrollment Form, I am aware that for assignment of benefit claims, the specialty pharmacy may ship product upon verification of benefits and collection of applicable co-pay. I understand that if there is no co-pay, the patient may not be contacted.

- CSCN, in whole or in part, directly or indirectly, to an Affiliate or NewCo (as defined in the Patient Authorization section above). I understand that Merck and/or the applicable Affiliate or NewCo will notify me or my Practice in the event of such assignment or transfer, including whether new enrollment is necessary for the patient and the option for the patient to terminate participation in the Program. I understand that any future offerings by an Affiliate or NewCo may differ from the CSCN and will be subject to eligibility criteria, terms, and conditions established by an Affiliate or NewCo that could affect my patient's participation in the future.
- I verify that the information provided is complete and accurate to the best of my knowledge.
- I acknowledge the following: Merck has retained Lash, a subsidiary of AmerisourceBergen, a supplier of reimbursement support, to support the CSCN. Information and questions related to the information provided in response to the submission of this form should be referred directly to Lash. Merck personnel are not aware of patient coverage information and are not permitted to discuss such information with customers. Communications in response to this form will be prepared for me by Lash, providing reimbursement assistance support for Merck products pursuant to an agreement with Merck, in response to my request for insurance coverage information regarding my patient. The information provided will be based on statements of individuals not affiliated with Lash, the CSCN, or Merck. Neither Lash, the CSCN, nor Merck make any warranties, expressed or implied, about the accuracy of this information. Insurance coverage status can change over time based on a variety of factors, including processing of additional claims that impact deductibles and/or coverage limits, changes in benefit design, and a patient's change in insurance carrier. Any coverage information provided to me in response to this request is intended for my and my patient's reference only and does not guarantee current or future coverage for any Merck product. Individual patient coverage information is provided to the extent that information is made available by the insurance plan.

Prescriber original signatur	e:	Date:	
Prescriber (please print): <u>J</u>			

To report an adverse event for a specific Merck product, including death due to any cause, please contact the Merck National Service Center at 800-444-2080.

CUSTOMER SUPPORT CENTER PHONE: 844-NEX-4321 (844-639-4321) • FAX: 844-232-2618

